表紙
市場調查報告書

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析

Histone Deacetylase 6 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 363572
出版日期 內容資訊 英文 149 Pages
訂單完成後即時交付
價格
組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析 Histone Deacetylase 6 - Pipeline Review, H2 2020
出版日期: 2020年10月30日內容資訊: 英文 149 Pages
簡介

本報告提供組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的概要

治療藥的開發

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各開發階段

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各適應症

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):企業開發中的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):大學/機關開發中的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的治療藥的開發企業

  • Acetylon Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • HitGen LTD
  • Kancera AB
  • Karus Therapeutics Limited
  • Lycera Corp.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • OncoHoldings, Inc.
  • Quimatryx, S.L.
  • Sigma-Tau S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • 武田藥品工業
  • TetraLogic Pharmaceuticals

藥物簡介

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):暫停中的計劃

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2677TDB

Summary:

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 52 molecules. Out of which approximately 43 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 3, 1, 27 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Charcot-Marie-Tooth Disease, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Charcot-Marie-Tooth Disease Type II, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Burkitt Lymphoma, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), CNS Lymphoma, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Fibrosis, Gallbladder Cancer, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Idiopathic Pulmonary Fibrosis, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Biliary Tract Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Tauopathies, Ulcerative Colitis, Unspecified and Vulvar Cancer.

The latest report Histone Deacetylase 6 - Pipeline Review, H2 2020, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

  • Introduction
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
  • Pipeline by ATP Biopharm, H2 2020
  • Pipeline by Augustine Therapeutics, H2 2020
  • Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020
  • Pipeline by Convalife, H2 2020
  • Pipeline by CStone Pharmaceuticals Co Ltd, H2 2020
  • Pipeline by Curis Inc, H2 2020
  • Pipeline by Eikonizo Therapeutics Inc, H2 2020
  • Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2020
  • Dormant Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020